{"id":"routine-three-drug-antiretroviral-prophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3142645","moleculeType":"Small molecule","molecularWeight":"2553.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Routine three-drug antiretroviral prophylaxis typically combines agents from different drug classes (such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or integrase inhibitors) to prevent HIV infection through complementary mechanisms. This multi-drug approach reduces the likelihood of viral resistance and provides more potent suppression of HIV replication than monotherapy.","oneSentence":"A combination of three antiretroviral drugs that work together to suppress HIV replication by targeting different stages of the viral lifecycle.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:16.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV post-exposure prophylaxis (PEP)"},{"name":"HIV pre-exposure prophylaxis (PrEP)"},{"name":"HIV treatment"}]},"trialDetails":[{"nctId":"NCT00753324","phase":"PHASE4","title":"Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-05","conditions":"HIV Infections","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Routine three-drug antiretroviral prophylaxis","genericName":"Routine three-drug antiretroviral prophylaxis","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination of three antiretroviral drugs that work together to suppress HIV replication by targeting different stages of the viral lifecycle. Used for HIV post-exposure prophylaxis (PEP), HIV pre-exposure prophylaxis (PrEP), HIV treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}